Prognostic Factors Predicting Bleeding After Discharge Requiring Readmission After Thulium Laser Enucleation of the Prostate (ThuLEP)
Abstract
Objectives Postoperative haematuria is a feared complication following prostate enucleation, and it may occur
even weeks after discharge. We evaluated the risk of bleeding after discharge and its predictive factors in patients who
underwent Thulium laser enucleation of the prostate (ThuLEP).
Methods Between January 2015 and December 2018, patients with surgical indication for benign prostatic
hyperplasia underwent ThuLEP in 4 urology departments. All procedures were performed by experienced urologists.
Postoperative haematuria was defined as macroscopic haematuria occurring 7 days after discharge. Readmission
rate due to macroscopic haematuria was assessed. Logistic regression models tested for predictors of postoperative
bleeding requiring readmission.
Results Overall, 748 patients were included, and 52 (6.9%) of them were readmitted after discharge because of
macroscopic haematuria. No cases of deep venous thrombosis or pulmonary embolism were diagnosed. Mean
length of stay for surgical treatment was 2.1 days, and mean hospitalization for readmission was 5.6 days. None of
the readmitted patients required reintervention, while 46.1% of them required blood transfusions. Diabetes mellitus
(P < 0.05), a long bridge of oral anticoagulant drugs with low molecular weight heparin (LMWH) (P < 0.05) and
history of constipation (P < 0.05) were significant predictors of readmission after discharge due to macroscopic
haematuria.
Conclusions Patients with a clinical history of diabetes mellitus or constipation and patients who undergo a long
bridge of oral anticoagulant therapy with LMWH are at higher risk of bleeding requiring readmission after ThuLEP.
The Société International d'Urologie (SIU), which owns and publishes the Société International d'Urologie Journal (SIUJ), does not require authors of papers published in the journal to transfer copyright. Instead, we ask authors to grant an exclusive licence that allows us to publish the article in SIUJ (and any derivative or related products or publications) and that allows us to sub-license such rights and exploit all subsidiary rights.
Authors retain the right to use their own articles for their own non-commercial purposes without seeking explicit permission from SIU.
The SIUJ publication licence expressly defines “non-commercial” as “not primarily intended for or directed towards commercial advantage or monetary compensation.” Although no activity is completely disconnected from commercial activity, the following are generally considered to be non-commercial uses:
- Reproduction of a reasonable number (no more than 100) of print copies of the published paper for personal use (e.g., sharing with colleagues, including in grant applications).
- Posting a copy of the published version of the paper on the author’s own or their institution’s website. The article must be accompanied by this statement: ‘This article has been published in the SIUJ: [full citation; link]’.
- Inclusion of the paper in a course pack, with a maximum of 100 copies to be used in the author’s institution. The copies must include the following acknowledgement: ‘This article has been published in the SIUJ: [full citation; link].’
As the distinction between commercial and non-commercial is not always clear, authors are strongly advised to seek permission from SIU for any use that may be considered to have a commercial aspect.
We ask the corresponding author to read the terms of the licence and then to grant this exclusive licence on behalf of all authors by indicating agreement to the following statement:
The corresponding author has the right to grant on behalf of all authors and does grant on behalf of all authors, an exclusive licence on a worldwide basis to the SIU and its licensees to permit this article (if accepted) to be published in the SIUJ and any other SIU products and publications and to exploit all subsidiary rights, as set out in our licence agreement.
Review and Decision
Most submissions will be reviewed by a senior editor within 2 weeks. Many manuscripts will be rejected at this point for a variety of reasons, including subject matter outside the scope of the SIUJ, flawed design, discredited or outdated methodology, poor organization or presentation, failure to conform to ethical requirements, and apparent plagiarism.The remaining manuscripts will be sent for peer review. The SIUJ uses a single-blind process: reviewers know the identity of the authors, but the authors are not told who has reviewed their manuscript, and SIUJ ensures that potentially identifying information is removed from comments sent to them. Reviewers are asked to make their recommendations within 10 days, after which a senior/specialist editor will consider their comments and recommend provisional acceptance dependent on satisfactory revision, acceptance without revision, or rejection. Authors should receive a final decision within 4 to 6 weeks of submission.
